British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005)

HIV Medicine

Volumn 6, Issue SUPPL. 2, 2005, Pages 1-61

  Gazzard, Brian ^a   Anderson, J ^b   Babiker, A ^b   Boffito, M ^b   Brook, G ^b   Churchill, D ^b   Collins, S ^b   Fisher, M ^b   Freedman, A ^b   Geretti, A M ^b   Johnson, M ^b   Khoo, S ^b   Leen, C ^b   Nair, D ^b   Peters, Barry ^b   Phillips, Andrew ^b   Pillay, Deenan ^b   Pozniak, Anton ^b   Walsh, John ^b   Wilkins, Ed ^b   Williams, Ian ^b   more..

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b BHIVA Secretariat Mediscript Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COST BENEFIT ANALYSIS; DIARRHEA; DISORIENTATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSPHORIA; ETHNOLOGY; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLACTATEMIA; JAUNDICE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTE COUNT; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MOOD DISORDER; MYOPATHY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NIGHTMARE; PARANOIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; SERODIAGNOSIS; SEX DIFFERENCE; SIDE EFFECT; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; SUICIDE ATTEMPT; SUPERINFECTION; TERATOGENICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; UNITED KINGDOM; URINARY TRACT DISEASE; VIRUS LOAD; VIVID DREAM;

EID: 22844432208     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.0311b.x     Document Type: Review

References (448)

1. Spartac Trial. http://www.aidsmap.com (accessed on 22 April 2005).
2. Richter A, Pladevall M, Manjunath R et al. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med 2005; 6: 79-90.
3. de Ronde A, van Dooren M, van Der Hoek L et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75: 595-602.
4. Pao D, Fisher M, Hue S et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19: 85-90.
5. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-188.
6. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
7. Violin M, Cozzi-Lepri A, Velleca R et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18: 227-235.
8. UK Collaborative Group on HIV Drug Resistance, UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19: 487-494.
9. Corzillius M, Muhlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antivir Ther 2004; 9: 27-36.
10. Lalezari JP, Henry Y, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-2185.
11. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-2195.
12. Hicks C et al. RESIST-1: a phase 3 randomized, controlled, open-label multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 31-November 2 2004 [Abstract H-1137a].
13. Cahn P et al. 24-week data from RESIST-2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV + patients. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, 2004 [Abstract PL14.3].
14. Bae A, Waters J, Margot N, Borroto-Esoda K, Miller M. Pre-existing L74V is a risk factor for virological non-response and development of K65R in patients taking tenofovir DF (TDF). Antivir Ther 2004; 9: S174.
15. Mellors J, Palmer S, Nissley D et al. Low-frequency NNRTI-resistant variants contribute to failure of efavirenz-containing regimens. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004 [Abstract 39].
16. Wirden M, Delaugerre C, Marcelin AG et al. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 2004; 48: 644-647.
17. Barbour JD, Hecht FM, Wrin T et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18: 1683-1689.
18. Brenner B, Routy JP, Quan Y et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18: 1653-1660.
19. Delaugerre C, Morand-Joubert L, Chaix ML et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9: 415-421.
20. Gandhi RT, Wurcel A, Rosenberg ES et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003; 37: 1693-1698.
21. Little SJ, Koelsch KK, Ignacio CC et al. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. 11th CROI. San Francisco, 2004 [Abstract 36LBPao 2004].
22. Pao D, Andrady U, Clarke J et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37: 1570-1157.
23. Wirden M, Simon A, Schneider L et al. Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs. J Clin Microbiol 2003; 41: 2713-2715.
24. Geretti AM. Essential benefits of nucleoside analogue regimens in failing therapy. J HIV Ther 2004; 9: 28-33.
25. Royal College of Physicians. Clinical Effectiveness and Evaluation Unit. HIV Testing for Patients Attending General Medical Services - National Guidelines. London, The Royal College of Physicians, 2005.
26. Medical Foundation for AIDS and Sexual Health. Recommended Standards for NHS HIV Services. Medical Foundation for AIDS and Sexual Health, London, 2003. www.medfash.org.uk (accessed on 17 May 2005).
27. Madge S, Matthews P, Singh S, Theobald N. HIV in Primary Care. Medical Foundation for AIDS and Sexual Health, London, 2004. www.medfash.org.uk (accessed on 17 May 2005).
28. Association of British Insurers. Statement of Best Practice on HIV Insurance. Association of British Insurers. London, 2004. www.abi.org.uk (accessed on 16 May 2005).
29. Pozniak A, Gazzard B, Anderson J et al. British HIV Association (BHIVA) guidelines for the treatment on HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4 (Suppl. 1): 1-41.
30. Katlama C, Berger D, Bellos N et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of two 96-week multinational dose-finding trials. 12th Conference on Retroviruses and Opportunistic Infections. Boston, 2005 [Abstract Oral 164LB].
31. Gazzard B, Pozniak A, Arasteh K et al. TMC 125, a next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-experienced HIV-1-infected individuals with phenotypic NNRTI resistance. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002 [Abstract 4].
32. The SMART Study. http://www.smart-trial.org/about.htm (accessed on 25 April 2005).
33. Health Protection Agency (HIV/STI Department, Communicable Disease Surveillance Centre). AIDS/HIV Quarterly Surveillance Tables Cumulative UK Data To End September 2004 No. 64: 04/3 October 2004.
34. Green G, Smith R. The psychosocial and health care needs of HIV-positive in the United Kingdom: a review HIV Medicine. 2004; 5(Suppl. 1): 5-46.
35. Palacio H, Kahn JG, Richards TA, Morin SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep 2002; 117: 233-251; discussion 231-2.
36. Department of Health, African HIV Policy Network, National AIDS Trust HIV and AIDS in African communities: a framework for better prevention and care. 2004.
37. Guidelines for the Management of HIV infection in Pregnant Women and the Prevention of Mother-to-Child Transmission of HIV. Draft http://www.bhiva.org.uk January 2005.
38. Sabin CA, Smith CJ, Gumley H et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18: 2145-2151.
39. Boyd AE, Murad S, O'Shea S, de Ruiter A, Watson C, Easterbrook PJ. Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in South London. HIV Medicine 2005; 6: 59-65.
40. Health Protection Agency's Centre for Infection. CD4 Surveillance Scheme. Colindale, London. http://www.hpa.org.uk/infections/topics_02/hiv_and_sti/hiv/epidemiology/ files/hars_slideset.zip (accessed 7 June 2005).
41. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475-482.
42. Giordano TP, White AC Jr, Sajja P et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003; 32: 399-405 (a).
43. McNaghten AD, Hanson DL, Dworkin MS, Jones JL., Adult/adolescent spectrum of HIV disease group. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32: 499-505.
44. Easterbrook PJ, Phillips AN, Hill T et al. U K The CHIC Study Patterns and predictors of antiretroviral drug use at treatment initiation in the UK. The XV International AIDS Conference. 2004 [Abstract TuPeB4543].
45. Maini UK, Gilson RJ, Chavda N et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996; 72: 27-31.
46. CASCADE Collaboration. Differences in CD4 + cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003; 34: 76-83.
47. Delmas AC, Jadand C, De Vincenzi I et al. Gender differences in CD4 + cell counts persist after HIV-1 infection. AIDS 1997; 11: 1071-1073.
48. Prinsa M, Robertsonb JR, Brettlec RP et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13: 2361-2364.
49. Prins M, Meyer L. Considering the dynamics of HIV infection by sex, should treatment guidelines be revisited? The XV International AIDS Conference, Bangkok, 2004. Abstract TuPeB4539.
50. Napravnik S, Poole C, Thomas JC, Eron JJ. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002; 31: 11-19.
51. Giordano TP, Wright JA, Hasan MQ, White AC Jr, Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003; 37: 433 (b).
52. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr 2002; 29: 197-202.
53. Moore AL, Kirk O, EuroSIDA group et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32: 452-461.
54. Patterson K, Napravnik S, Eron J et al. Age and sex effect on response to initial HAART. Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 22-25 February 2005 [Abstract 596].
55. Moore AL, Mocroft A, Madge S et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr 2001; 26: 159-163.
56. Smith CJ, Sabin CA, Youle MS et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190: 1860-1868.
57. Anastos K, Schneider M. Effect of race on the response to highly-active antiretroviral therapy. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004 [Abstract 560].
58. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 1139-1146.
59. Staehelin C, Rickenbach M, Swiss HIV Cohort Study et al. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003; 17: 2237-2244.
60. Jensen-Fangel S, Pedersen L, Pedersen C et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35: 1541-1548.
61. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
62. Walmsley SL, Saskin R, Raboud J, Thompson C. Safety and efficacy of highly active antiretroviral therapy (HAART) in a clinical cohort of HIV infected Women. The XV International AIDS Conference. 2004 [Abstract B10988].
63. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16: 1566-1568.
64. Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-129, Epub 13 December 2000.
65. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
66. Sanne I, Mommeja-Marin H, Hinkle J et al. Severe Hepatotoxicity Associated with Nevirapine Use in HIV-Infected Subjects. J Infect Dis 2005; 191: 825-829, Epub 10 February 2005.
67. Ribaudo H, Clifford D, Gulick R et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A5095/A5097s. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004 [Abstract 132].
68. Haas D, Ribaudo H, Kim R et al. A common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG study NWCS214. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004 [Abstract 133].
69. Easterbrook PJ, Waters A, Murad S et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 2003; 4: 321.
70. Symonds W, Cutrell A, Edwards M et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002; 24: 565-573.
71. Clark RA, Theall K. Population-based study evaluating association between selected antiretroviral therapies and potential oral contraceptive failure. J Acquir Immune Defic Syndr 2004; 37: 1219-1220.
72. Schindl A, Rieger A, Wagner OF, Quehenberger P. Sex differences in HAART-associated dyslipidaemia. AIDS 2001; 15: 725-734.
73. Pernerstorfer-Schoen H, Jilma B, Perschler A et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001; 15: 725-734.
74. Galli M, Cozzi-Lepri A, LipoICoNa Study et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med 2002; 162: 2621-2628.
75. Mulligans K, Anastos K, Justman J et al. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 38: 18-22.
76. Raghavan S, Law M, El-Sadr W, Carr A. Ethnic differences in objective measures of lipodsytrophy (LD) The XV International AIDS Conference, Bangkok, 2004. Abstract no. WePeB5939.
77. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342: 1907-1909.
78. Phillips AN, Grabar S, for the EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 1999; 13: 2075-2082.
79. Hurwitz B. Legal and political considerations of clinical practice guidelines. BMJ 1999; 318: 661-664.
80. Staszewski S, Miller V, Sabin CA et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999; 13: 951-956.
81. Pozniak A. Surrogacy in HIV-1 clinical trials. Lancet 1998; 351: 536-537.
82. Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401-410.
83. Food and Drug Administration. Guidance For Industry (draft). Clinical Considerations For Accelerated and Traditional Approval of Antiretroviral Drugs Using Plasma HIV RNA Measurements. Washington DC, FDA. http://www.fda.gov/cder/guidance/3182dft.htm 1999.
84. Delta Coordinating Committee and Virology Group. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta trial: an extended virology study. AIDS 1999; 13: 57-65.
85. Mocroft A, Katlama C, Johnson MA et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356: 291-296.
86. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
87. Miller V, Staszewski S, Nisius G, Cozzi Lepri A, Sabin CA, Phillips AN. Risk of new AIDS diseases in people on triple therapy. Lancet 1999; 353: 463.
88. Weverling GJ, Mocroft A, Ledergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after the initiation of highly active antiretroviral therapy in HIV infection. Lancet 353: 1293-1298.
89. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344: 168-174.
90. Miller V, Phillips AN, Clotet B et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186: 189-197.
91. Ledergerber B, Lundgren JD, Walker AS et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62.
92. Fleming TR, Demets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
93. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers: are we being naive? J Infect Dis 1997; 175: 237-246.
94. Holkmann Olsen C, Gatell J, for the EuroSIDA Study Group et al. Risk of AIDS and death at given HIV-RNA and CD4 cell count levels, according to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319-330.
95. Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate end-points in AIDS clinical trials. JAMA 2001; 285: 777-784.
96. Phillips AN, Walker AS. Drug switching and virologic-based end-points in trials of antiretroviral drugs for HIV infection. AIDS 2004; 18: 365-370.
97. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. http://www.fda.gov/cder/guidance/index.htm October 2002.
98. D'Agostino RB. Non-inferiority trials: advances in concepts and methodology. Stat Med 2003; 22: 165-167.
99. Phillips AN. Trial and error: cross-trial comparisons of antiretroviral regimens. AIDS 25 2003; 17: 619-623.
100. Committee on Safety of Medicines. http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm (accessed on 20 May 2005).
101. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288: 2868-2879.
102. Poppa A, Davidson O, Deutsch J et al. British HIV Association (BHIVA)/British Association for Sexual Health and HIV (BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy (2003). HIV Med 2004; 5 (Suppl. 2): 46-60.
103. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-366.
104. Walsh JC, Pozniak AL, Nelson MR et al. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 2002; 30: 278-287.
105. Gallego O, de Mendoza C, Perez-Elias MJ et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 2001; 15: 1701-1706.
106. Bangsberg DR, Charlebois ED, Grant RM et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17: 1925-1932.
107. Bangsberg DR, Guzman D, Riley ED. Non nucleoside reverse transcriptase inhibitor (NNRTI) resistance occurs at lower levels of adherence then protease inhibitor (PI) resistance. 15th International AIDS Conference. Bangkok, July 2004 [Abstract WePeB5820].
108. Parienti JJ, Massari V, Descamps D et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38: 1311-1316.
109. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53: 696-699.
110. Gulick RM et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-1861.
111. Gallant JE, Rodriguez AE, Weinberg W et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. Program and Abstracts of the 43rd Annual ICAAC. Chicago, IL, 14-17 September 2003 [Abstract H-1722a].
112. Podzamczer D, Ferrer E, Gatell JM et al. Early virologic failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. XIII International HIV Drug Resistance Workshop. Tenerife, Canary Islands, 8-12 June 2004 [Abstract 156].
113. Maitland D, Moyle G, Hand J et al. Early virological failure in persons with viral loads > 100 000 cps/mL and CD4 counts < 200/μL receiving didanosine (ddI)/tenofovir (TDF)/efavirenz (EFV): 12 week results from a randomised comparative trial. 7th International Congress on Drug Therapy in HIV infection. Glasgow, 14-18 November 2004 [Abstract PL2.5].
114. Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens 2000; 13: 184-190.
115. Baird MG, Bentley-Taylor MM, Carruthers SG et al. A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension: Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med 1984; 7: 95-102.
116. Goujard C, Bernard N, Sohier N et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr 2003; 34: 191-194.
117. Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns 2003; 50: 187-199.
118. Mannheimer S, Morse E, Matts J. Sustained Benefit from a Long-term Antiretroviral (AR) Adherence Intervention: Results of a Large Randomized Clinical Trial. 15th International AIDS Conference. Bangkok, July 2004 [Abstract LbOrB15].
119. Rawlings MK, Thompson MA, Farthing CF et al. Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34: 174-183.
120. Dilorio C, Resnicow K, McDonnell M, Soet J, McCarty F, Yeager K. Using motivational interviewing to promote adherence to antiretroviral medications: a pilot study. J Assoc Nurses AIDS Care 2003; 14: 52-62.
121. Pradier C, Bentz L, Spire B et al. Efficacy of an educational and counselling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 2003; 4: 121-131.
122. Wagner G, Kanouse D, Miller L et al. Cognitive-behavioural Intervention to Enhance Adherence to ART: A Randomized Clinical Trial (CCTG 578). 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2005 [Abstract 614].
123. Jones DL, Ishii M, LaPerriere A et al. Influencing medication adherence among women with AIDS. AIDS Care 2003; 15: 463-474.
124. Weber R, Christen L, Swiss HIV Cohort Study et al. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. Antivir Ther 2004; 9: 85-95.
125. Fischl M, Rodriguez A, Scerpella E. Impact of directly observed therapy on outcomes in HIV clinical trials. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000 [Abstract 71].
126. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis 2004; 38 (Suppl. 5): S409-13.
127. Kagay CR, Porco TC, Liechty CA et al. Modelling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. Clin Infect Dis 2004; 38 (Suppl. 5): S414-S420.
128. Witek J, Rockstroh J, Donatacci L. Adherence to enfuvirtide and to background antiretroviral therapy over 48 weeks and its impact on treatment efficacy. 15th International AIDS Conference. Bangkok, July 2004 [Abstract WePeB5822].
129. Chun T-W, Carruth L, Finzi D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-187.
130. Kinloch de Loes S, Hirschel BJ, Hoen B et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408-413.
131. Zhu T, Mo H, Wang N et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-1181.
132. Zhang L, Ramratnam B, Tenner-Racz K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-1613.
133. Markowitz M, Vesanen M, Tenner-Racz K et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type-1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179: 527-537.
134. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655.
135. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-6110.
136. Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4 + T cell responses associated with control of viremia. Science 1997; 278: 1447-1450.
137. Rosenberg ES, Altfeld M, Poon SH et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523-526.
138. Walker BD, Rosenberg ES, Hay CM, Basgoz N, Yang OO. Immune control of HIV-1 replication. Adv Exp Med Biol 1998; 452: 159-167.
139. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959-969.
140. Lisziewicz J, Rosenberg E, Lieberman J et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340: 1683-1684.
141. Kaufmann DE, Lichterfeld M, Altfeld M et al. Limited Durability of Viral Control following Treated Acute HIV Infection. PLoS Med 2004; 1: e36. Epub 26 October 2004.
142. Lori F, Lisziewicz J. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis 2000; 30 (Suppl. 2): S193-S197.
143. Rizzardi GP, Capiluppi B, Tambussi G et al. Effect of cyclosporin A in combination with highly active antiretroviral therapy in primary HIV-1 infection. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 759].
144. Khonkarly M, Tambussi G, Ciuffreda D et al. Long term benefit of Cyclosporin A coupled with highly active antiretroviral therapy in primary HIV-1 infection. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 22-15 February 2005 [Abstract 567].
145. Miller J, Finlayson R, Smith D et al. The occurrence of lipodystrophic phenomena in patients with primary HIV infection (HIV) treated with antiretroviral therapy (ARV). VII European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, 23-27 October 1999 [Abstract 519].
146. Goujard C, Boufassa F, Deveau C, Laskri D, Meyer L. Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection. AIDS 2001; 15: 282-284.
147. Fidler S, Oxenius A, Brady M et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 2049-2052.
148. Philips AN, Smith GD, Johnson MA. Will we ever know when to treat HIV infection? BMJ 1996; 313: 608-610.
149. Gupta SB, Gilbert RL, Brady AR, Livingstone SJ, Evans BG. CD4 cell counts in adults with newly diagnosed HIV infection. Results of surveillance in England and Wales, 199-98. CD4 Surveillance Scheme Advisory Group. AIDS 2000; 14: 853-861.
150. CASCADE Collaboration. Short-term risk of AIDS according to the current CD4 count and viral load in antiretroviral naive individuals or those treated in the monotherapy era. AIDS 2004; 18: 51-58.
151. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15: 2251-2257.
152. Miller V, Sabin CA, Phillips AN et al. The impact of protease inhibotor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000; 14: 2129-2136.
153. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568-2577.
154. Wood R, Team TS. Sustained efficacy of nevirapine (NVP) in combination with two nucleosides in advanced treatment-naive HIV infected patients with high viral loads: a B1090 substudy. XIII International AIDS Conference. Durban, South Africa, 28 June-3 July 2000 [Abstract WeOrB604].
155. Walmsely S, Bernstein B, King M et al. M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
156. Opravil M, Ledergerber B, Furrer H et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell could > 350 × 106/I. AIDS 2002; 16: 1371-1381.
157. Wang C, Vlahov D, Galai N et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. Journal of Infectious Diseases 2004; 190: 1046-1054.
158. Pallela JF, Delona-Knoll M, Cmiel JS et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4 + cell strata. Ann Intern Med 2003; 138: 620-626.
159. Sterling TR, Chaisson RE, Moore RD. Initiation of highly active antiretroviral therapy at CD4 + T lymphocyte counts of > 350 cells/μL: disease progression, treatment durability, and drug toxicity. Clin Infect Dis 2003; 36: 812-815.
160. Phillips AN, Lepri AC, Lampe F, Johnson M, Sabin CA. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003; 17: 1863-1869.
161. Egger M, May M, ART Cohort Collaboration et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
162. Matthews GV, Bower M, Mandalia S et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730-2734.
163. Bhaskaran K, Brettle R, Porter K, Walker AS, CASCADE Collaboration. Systemic non-Hodgkin lymphoma (NHL) in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS
164. Reeves I, Fisher M, Hill T, Sabin C, on behalf of the UK Collaborative HIV Cohort (CHIC) Steering Committee. CD4 counts and the risk of lymphoma in individuals with HIV in the UK. 11th Annual Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). Dublin, 2005 [Abstract 047].
165. Phair JP, Mellor JW, Detels R et al. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002; 16: 2455-2459.
166. Mellors JW, Munoz A, Giorgy JV et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
167. Benhamou Y, Bochet M, Di Martino V et al. Fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
168. Puoti M, Bonacini M, Spinetti A et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183: 134-137.
169. Benhamou Y, Di Martiono V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-287.
170. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
171. Moyle G. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs 2001; 61: 19-26.
172. Walmsely S, Bernstein B, M98-863 Study Team et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
173. van Leth F, Andrews S, Grinsztejn B et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19: 463-471.
174. Moyle GJ, Baldwin C, Dent N et al. Management of protease inhibitor (PI)-associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons. XXXIV Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 26-29 September 1999 [Abstract 2064].
175. Goldenberg D, Bolye B. Psychiatric safety of efavirenz. 13th International AIDS Conference. Durban, 2000 [Abstract WePeB4238].
176. Shafran S, Lefebvre E, Baril J et al. Retrospective analysis of factors associated with discontinuation of EFV due to adverse effects. 1st International AIDS Society Conference an HIV Pathogenesis and Treatment. Buenos Aires, 2001 [Abstract 537].
177. Kaspar R. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash. XXXVIII Interscience Conference in Antimicrobial Agents and Chemotherapy. San Diego, CA, 24-27 September 1998 [Abstract I-64].
178. Important change in SUSTIVA (efavirenz) package insert - change from pregnancy category C to D. Company-initiated warning letter, Bristol-Myers Squibb Company, March 2005.
179. Barreiro P, Soriano V, Casas E et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14: 2153-2157.
180. Montaner J, Giglotti M, Cahn P et al. The effects of a short course of prednisone on the incidence of rash associated with nevirapine (Viramune). XIII World AIDS Conference. Durban, South Africa, 24 June-3 July 2000 [Abstract WePeB1378].
181. Hammer SM, Squires KM, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-733.
182. Harrigan PR, Stone C, the CNA 2001 Investigative Group et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J Infect Dis 2000; 181: 912-920.
183. Murphy RL, Sanne I, Cahn P et al. Dose ranging, randomized, clinical tral of atazanavir with lamivudine and stavudine in antiretroviral naive subjects: 48 week results. AIDS 2003; 17: 2603-2614.
184. Dragsted U, Gerstoft J, Pedersen C et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency type-1 infected patients: the MaxCMin1 trial. J Infect Dis 2003; 188: 634-642.
185. Youle M, Gerstoft J, Fox Z et al. The final week 48 analysis of a phase IV randomized open label multicentre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): the MaxCMin2 trial. 9th European AIDS Conference. Warsaw, 2003 [Abstract F 11/3].
186. Sanne I, Piliero P, Squires K et al. Results of a phase 2 clinical trial at 48 weeks (AI424-067): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral naive subjects. J AIDS 32: 18-29.
187. Squires K, Lazzarin A, Gatell JM et al. Comparison of once daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J AIDS 2004; 36: 1011-1019.
188. Staszewski S, Keiser P, Montaner J et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomised equivalence trial. JAMA 2001; 285: 1155-1163.
189. Gulick RM, Ribaudo HJ, Shikuma CM et al. ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract Oral 41].
190. Robbins GK, De Gruttola V, Shafer RW et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2293-2303.
191. Jemsek J, Hutcherson P, Harper E. Poor virological responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2004 [# 51].
192. Landman R, Peytavin G, Descamps D et al. Low genetic barrier to resistance is a possible cause of early virological failures in once daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. 11th CROI. San Francisco, 2004 [#52].
193. Staszewski S, Morales JM, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865-1873.
194. DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39: 1038-1046.
195. Podzamczer D, Ferrer E, Consiglio E et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7: 81-90.
196. Curtis H, Sabin CA, Johnson MA. Findings from the first national clinical audit of treatment for people with HIV. HIV Med 2003; 4: 11-17.
197. Gazzard B, De Jesus E, Campo R. The combination of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) has significantly greater response vs. fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients: a 24 week preliminary analysis. 44th ICAAC. Washington, DC, 2004 [Oral presentation H-1137c].
198. Gathe J, Podzamczer D, Johnson M et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral naive patients: 48 week results. 11th CROI. San Francisco, 2004 [Abstract 716].
199. Gallant JE, Staszewski S, Pozniak A et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients. A 3-year randomized trial. JAMA 2004; 292: 191-201.
200. Moyle G, DeJesus E, Cahn P et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen once daily in antiretroviral combination study. J Acquir Immune Defic Syndr 2005; 38: 417-425.
201. Podzamczer D, Ferrer E, Sanchez P et al. Toxicity and efficacy of 3TC/EFV associated with stavudine or abacavir in antiretroviral-naive patients: 48 week results of a randomized open and multicentre trial (ABCDE study). 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, 2004 [Abstract 783].
202. Bartlett JA, Johnson J, Herrera G et al. Initial therapy with abacavir + lamivudine (ABC + 3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS). Program and Abstracts of the 15th International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 [Abstract TuPeB4544].
203. Gathe JC Jr, Ive P, Wood R et al. SOLO: 48-week efficacy and safety comparison of once daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18: 1529-1537.
204. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Homvariant. PNAS 2004; 101: 4180-4185.
205. Walmsley S, Bernstein HB, King MK et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
206. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
207. Maggiolo F, Ripamonti D, Migliorino G et al. Virologic efficacy of three once-a-day HAART regimens. Planned interim analysis. International Congress on Drug Therapy HIV. 14-18 November 2004; 7: [Abstract P10].
208. Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naive patients. A randomized trial. JAMA 2004; 292: 180-190.
209. Hayden R, Rode R, for the MOO-267 Study Group et al. Evaluation of side effect tolerability and quality of life (QOL) measures in patients after substitution of their PI/NNRTI with lopinavir/ritonavir (LPv/r). Antiviral Therapy 2003; 8 (Suppl. 1): S39 [Abstract 557].
210. Arnaiz JA, Mallolas J, BEST Study Team et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003; 17: 831-840.
211. Mallon PWG, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-979.
212. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipatrophy. J Acquir Immune Defic Syndr Hum Retrovirol 2003; 33: 22-28.
213. http://www.aidsmap.com/treatments (accessed on 25 April 2005).
214. Moyle G, Sabin C, Cartledge J et al. A 48-week, randomized, open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analogue in persons with lipoatrophy and sustained virological suppression on HAART. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2005 [Abstract 44LB].
215. Milinkovic A, Lopez S, Vidal S et al. A randomised open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. 12th Conference on Retroviruses and Opportunistic Infections. Boston, 2005 [Abstract 857].
216. Gunthard HF, Frost SD, Leigh-Bronw AJ et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999; 73: 9404-9412.
217. Opravil M, Hirschel B, Swiss HIV Cohort Study et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-1260.
218. Raffi F, Esnault JL, Reliquet V et al. The Maintavir Study, substitution of a non-nucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients with undetectable plasma HIV-1 ma: 18 months follow-up. XXXX Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17-20 September 2000 [Abstract 474].
219. Winston A, Pozniak A, Smith A et al. Dose escalation or immediate full dose when switching from efavirenz-to nevirapine-based HAART?, IX Annual Conference of the British HIV Association. Manchester, UK, 24-26 April 2003 [Abstract 011].
220. Cunningham CK, Chaix M-L, Rekacewicz C et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186: 181-188.
221. Jackson JB, Becker-Pergola G, Guay LA et al. Identification of the K103 N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14: F111-F115.
222. Fagard C, Oxenius A (for the Swiss HIV Cohort Study) et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163: 1220-1226.
223. Dybul M, Chun TW, Yoder C et al. Short-cycle intermittent HAART, a pilot study. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL., 4-8 February 2001 [Abstract 354].
224. Fauci AS. Host factors in the pathogenesis of HIV disease: implication for therapeutic strategies. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract S16].
225. Fisher M, Hafner R, Schneider C et al. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 2003; 24: 195-199.
226. Cardiello PG, Hassink E, Ananworanich J et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40: 594-600.
227. Pilcher CE, Miller WC, Beatty ZA, Eron JJ. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virological relapse on antiretroviral therapy. AIDS 1999; 13: 1337-1342.
228. Greub G, Cozzi Lepri A, Ledergerber B et al. Lower level HIV viral rebound and blips in patients receiving potent antiretroviral therapy. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 522].
229. Havlir D, Levitan D, Bassett R, Gilbert P, Richman D, Wong J. Prevalence and predictive value of interment viraemia in patients with viral suppression. Antiviral Ther 2000; 5 (Suppl. 3): 89 [Abstract 112a].
230. Nettles RE, Kiefer TL, Kwon P et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817-829.
231. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4 + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficience virus infection. J Infect Dis 2000; 181: 946-953.
232. Pozniak A, Plattneberg A, Rozenbaum W. A 48 week final analysis from a phase III double-blind placebo controlled study in antiviral experienced patients (study 907). XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract WeOrB1266].
233. Rouse E, Gerondelis P, Paulsen D et al. Clonal analysis of week 12 virologic non-responders receiving tenofovir/abacavir/lamivudine in ESS30009. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 22-25 February 2005 [Abstract 720].
234. Johnson J, Li JF, Morris L et al. Resistance emerges in the majority of women provided intrapartum single-dose nevirapine. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 22-25 February 2005 [Abstract 100].
235. Benson CA, Decks SG, Brun SC et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185: 599-607.
236. Hsu A, Isaacson J, Brun S et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 350-359.
237. Johnson M, Grinsztejn B, Rodriguez C et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/rotonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 153-162.
238. Preliminary 48-week data from phase 111 study of 433908, an investigational HIV protease inhibitor. Vertex Pharmaceuticals Press Release, 24 July 2003.
239. Bak Dragsted U, Gerstoft J, for the MaxCmin 2 trial group et al. The interim analysis of a phase IV, randomised, !open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/ 100 mg bid) in adult HIV-1 infection: The MaxCmin2 Trial. 6th International Congress on Drug Therapy in HIV Infection. Glasgow, 2002 [Abstract LB PL14.5].
240. Hammer SM, Squires KM, Hughes MD et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
241. Montaner J, Chung J, Guimaraes D et al. A treatment staging proposal derived from a post-hoc analysis of the 48 week results from the TORO studies. 15th International AIDS Conference. Bangkok, 2004 [Abstract TuPEB4483].
242. Sabin A, Hill T, on behalf of the UK CHIC Steering Committee et al. How long will the benefits of highly active antiretroviral therapy (HAART) last? Treatment exhaustion among individuals infected with HIV in the UK: a multicentere cohort study. BMJ 2005; 330: 695-698.
243. Brun-Vézinet F, Boucher C, Loveday C et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Delta Virology Working Group and Coordinating Committee. Lancet 1997; 350: 970-971.
244. Loutfy M, Walmsley SL, Mullin C, Perez G, Neaton J. CD4 + cell increase to highly active antiretroviral therapy (HAART) at one year is predictive of clinical outcome despite incomplete viral suppression. Antivir Ther 2003; 8 (Suppl. 1): S218-S219 [Abstract 144].
245. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-480.
246. Jiang H, Deeks S, Kuritzkes DR et al. Assessing resistance costs of highly active antiretroviral therapy via measures of future drug options. J Infect Dis 2003.
247. Deeks SG, Barbour JD, Grant RM et al. Duration and predictors of CD4 + T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16: 201-207.
248. Carpenter CCJ, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA panel. JAMA 2000; 283: 381-390.
249. Centers for Disease Control and Prevention. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (The Living Document). HIV/AIDS Treatment Information Service (ATIS), Atlanta, GA. http://www.hivatis.org April 2001.
250. Gazzard B, Moyle G, on behalf of the BHIVA Guidelines Writing Committee et al. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-316.
251. Clevenbergh P, Durant J, Verbiest W et al. Phenotypic analysis of the Viradapt study: correlation with genotypic resistance and PI plasma levels. Antiviral Ther 2000; 5 (Suppl. 3): 71-72.
252. Lorenzi P, Opravil M, Hirschel B et al. Impact of drug resistance on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13: F17-F21.
253. Workman C, Mussen R, Sullivan J. Salvage therapy using six drugs in heavily pretreated patients. V Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 31 January-5 February 1998 [Abstract 426].
254. Katlama C, Dominguez S, Duvivier C et al. Long-term benefit of treatment interruption in salvage therapy (GIGAHAART ANRS 097). X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 68].
255. Monataner J, Harringan PR, Jahnke N et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001; 15: 61-69.
256. Miller V, Sabin C, Hertogs K et al. Virological and immunological effects of treatment interruptions in Hiv-1 infected patients with treatment failure. AIDS 2000; 14: 2857-2867.
257. Cozzi-Lepri A, Phillips AN, Miller V et al. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther 2003; 8: 127-136.
258. Deeks S, Wrin T, Hoh R et al. Response to salvage therapy in patients undergoing a structured treatment interruption. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 292].
259. Lawrence J et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349: 837-846.
260. Katlama C, Dominguez S, Gourlain K et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18: 217-226.
261. Lawrence J, Mayers D, the study CPCRA 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS et al. CPCRA 064: A randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 67].
262. Kyriakides TC, Babkier, Singer J et al. An open-label randomized clinical trail of novel therapeutic strategies for HIV-infected patients in whom atniretorivral therapy has fialed: rationale and design of the OPTIMA trial. Controlled Clin Trials 2003; 24: 481-500.
263. Leith J, Walmsley S, Katlama C et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV) amprenavir (APV), or lopinavir (LPV): interim analysis of BI118 2.51. Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, 1-3 April 2004 [Abstract 5.1].
264. Katlama C, Arasteh K, Clotet B et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, 2003 [Abstract LB2].
265. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004; 9: 695-702.
266. Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189: 2174-2180.
267. Bennet D, McCormick L, Kline R et al. U.S. Surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 22-25 February 2005 [Abstract 674].
268. Weinstein MC, Goldie SJ, Losina E et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134: 440-450.
269. Sax PE, Islam R, Losina E et al. Should resistance testing be done in antiretroviral-naive patients? A cost-effectiveness analysis. XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract MoPeB3129].
270. Harrigan PR, Hogg RS, Dong WW et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 1:191: 339-347.
271. Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. The Lancet 1999; 353: 2195-2199.
272. Baxter JD, Mayers DL, Wentworth DN et al. A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14: F83-F93.
273. Tural C, Ruiz L, Holtzer C et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209-218.
274. Cingolani A, Antinori A, Rizzo MG et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomised study (ARGENTA). AIDS 2002; 16: 369-379.
275. Cohen CJ, Hunt S, Sension M et al. A randomised trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-588.
276. Haubrich RH, Kemper CA, Hellmann NS et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005; 19: 295-302.
277. Meynard JL, Vray M, Morand-Joubert L et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomised trial. AIDS 2002; 16: 727-736.
278. Blanco JL, Valdecillos G, Arroyo JR et al. A prospective randomised study on the usefulness of genotypic resistance tests versus real phenotypic resistance tests in heavily pretreated patients with virological failure (VIHRES study). XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract TuPeB4624].
279. Wegner SA, Wallace MR, Aronson NE et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004; 38: 723-730.
280. Mazzotta F, Lo Caputo S, Torti C et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 2003; 32: 268-280.
281. Perez-Elias MJ, Garcia-Arota I, Munoz V et al. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir Ther 2003; 8: 577-584.
282. Torre D, Tambini R. Antiretroviral drug resistance testing in patients with HlV-1 infection: a meta-analysis study. HIV Clin Trials 2002; 3: 1-8.
283. Loveday C, Dunn DT, Green H, Rinehart A, McKenna P, on behalf of the ERA steering committee. XII international HIV Drug Resistance Workshop. Cabo del Sol, Mexico, 10-14 June 2003. http://www.ctu.mrc.ac.uk/penta/trials/htm
284. Devereux HL, Youle M, Johnson AM, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123-127.
285. International AIDS Society-USA Drug Resistance Mutations Group. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12: 119-124.
286. Zachary KC, Hanna GJ, D'Aquila RT. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. Clin Infect Dis 2001; 33: 2075-2077.
287. Haubrich RH, Kemper CA, Hellman NS et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16: F33-F40.
288. Whitcomb JM, Huang W, Limoli K et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002; 16: F41-F47.
289. Tozzi V, Zaccarelli M, Narciso P et al. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis 2004; 189: 1688-1695.
290. Brenner B, Turner D, Oliveira M et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17: F1-F5.
291. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15: S171-S181.
292. Burger D, Boyd M, Duncombe C et al. Pharmaocinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob. Chemother 2003; 51: 1231-1238.
293. Garraffo R, Lavrut T, Pierre B, Durant et al. Efavirenz and nevirapine concentration-effect retlationships in HIV-infected patients pharmacologically followed by routine therapetuc drug monitoring (TDM). IV International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France, 27-29 March 2003 [Abstract 26].
294. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-2400.
295. La Porte C, van der Ende M, Gyssens I et al. Gender differences in nevirapine and efavirenz pharmacokinetics. 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, 27-29 March 2003 [Abstracts 10: P 3.1 and 15: P 3.6].
296. Back D, Gatti G, Fletcher C et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 (Suppl. 1): S5-S37.
297. Veldkamp AI, Weverling GJ, Lange JAM et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1 infected individuals. AIDS 2001; 15: 1089-1095.
298. Veldkamp AI, van Heeswijk RPG, Mathot RAA et al. Evaluation of exposure-response relationships for the non-nucloeside reverse transcriptase inhibitor (NNRTI) nevirapine in a cohort of HIV-infected individuals. II International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands, 2-4 April 2001 [Abstract 5.4].
299. Marzolini C, Telenti A, Decostered LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nerous system side effects in Hiv-1 infected patients. AIDS 2001; 15: 71-75.
300. van Leth F, Kappelhoff B, the 2NN Study group et al. Minimum Plasma Concentrations of Nevirapine and Efavirenz in Relation to Virologic Failure in Antiretroviral-naive Patients. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 22-25 February 2005 [Abstract 80].
301. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-478.
302. Burger DM, van Rossum AM, Dutch Study Group for Children with HIV-1 Infection et al. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2001; 45: 701-705.
303. Merry C, Barry MG, Gibbons S, Mulcahy F, Back DJ. Improved tolerability of ritonavir derived from pharmocokinteic principles. Br J Pharmacol 1996; 42: 787.
304. Reijers ME, Weigel HM, Hart AA et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000; 14: 59-67.
305. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 25: 290-291.
306. Boffito M, Bonora S, Sinicco A, Raiteri R et al. Lopinavir plasma concentrations and lipid elevation patterns in patients on lopinavir/ritonavir-containing regimens. IV International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France, 27-29 March 2003 [Abstract P4.4].
307. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatine capsules) administration. Br J Clin Pharmacol 2001; 52: 255-264.
308. Gonzalez de Requena D, Bonora S, Canta F et al. Atazanavir Ctrough Is Associated with Efficacy and Safety: Definition of Therapeutic Range. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 22-25 February 2005 [Abstract 645].
309. Treluyer JM, Morini JP, Dimet J et al. High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002; 46: 4009-4012.
310. Gutierrez F, Padilla S, Masia M et al. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations. Antivir Ther 2004; 9: 105-113.
311. Fletcher CV, Anderson PL, Kakuda TN. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 8: 551-560.
312. Burger D, Hugen P, Reiss P et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17: 1157-1165.
313. Clevenbergh P, Garraffo R, Durant J et al. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002; 22: 2311-2315.
314. Bossi P, Peytavin G, Ait-Mohand H et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5: 352-359.
315. Mentré F, Duval X, Rey E et al. Prospective trial to evaluate how therapeutic drug monitoring of protease inhibitors increases virologic success and tolerance of HAART (COPHAR 2 - ANRS 111 trial). 12th CROI. Boston, 2005 [Abstract 639].
316. Nettles R, Kieffer T, Parsons T et al. Frequent sampling in virologically suppressed patients taking HIV protease inhibitors or non-nucleoside reverse transcriptase inhibitors defines intra-individual pharmacokinetic variability. 12th CROI. 2005 [Abstract 642].
317. Gonzalez de Requena D, Gallego O, Valer L, Jimenez-Nacher I, Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004; 20: 275-278.
318. Castagna A, Danise A, Hasson H et al. The normalized inhibitory quotient (NIQ) of Lopinavir is predictive of viral load response over 48 weeks in a cohort of highly experienced HIV-1-infected individuals. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 24-28 February 2002 [Abstract 128].
319. Bertz R, Li J, King M et al. Lopinavir inhibitory quotient predicts virologic response in highly antiretroviral-experienced patients receiving high-dose lopinavir/ritonavir. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004 [Abstract 134].
320. Marcelin AG, Lamotte C, Genophar Study Group et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2003; 47: 594-600.
321. Marcelin AG, Delaugerre C, Ktorza N et al. Genotypic and phenotypic inhibitory quotients as predictors of the virological response to ritonavir/amprenavir containing regimen in HIV-1 protease inhibitor experienced patients. Program and abstracts of the Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14-18 November 2004 [Plenary Session 6.5].
322. Xu F, Tomkins S, Yates P et al. Genotypic inhibitory quotient predicts response to fosamprenavir/ritonavir. Program and abstracts of the Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14-18 November 2004 [P143].
323. De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Hoetelmans RM, Cauda R. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. J Acquir Immune Defic Syndr 2004; 35: 359-366.
324. Valer L, De Mendoza C, Fortogene Spanish Study Group. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. AIDS 2002; 16: 1964-1966.
325. Casado JL, Moreno A, Sabido R et al. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS 2003; 17: 262-264.
326. Fletcher CV, Jiang H, Brundage RC et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004; 189: 1176-1184.
327. Shulman N, Zolopa A, Havlir D et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002; 46: 3907-3916.
328. Valdez H, McCallister S, Hall DB, Kohlbrenner VM, Mayers DL. Most highly treatment experienced tipranavir/ritonavir recipients achieve inhibitory quotients associated with large week 24 viral load reductions. Frontiers in Drug Development for Antiretroviral Therapies meeting, Montego Bay, Jamaica, 12-16 December 2004 [Abstract 039].
329. BMS warning. REYATAZ® (atazanavir sulfate) with or without Norvir® (ritonavir) and proton pump inhibitors should not be coadministered: important new pharmacokinetic data. Dear Doctor letter. December 2004.
330. Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother 2005; 49: 467-469.
331. Rublein JC, Donovan BJ, Hollowell SB et al. Effect of omeprazole on the plasma concentrations of indinavir in HIV-negative subjects. Single dose 800 mg IDV. Cmin and AUC were similar to historical control when IDV administered with 200 mg RTV. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003 [Abstract A-1611].
332. van Heeswijk R, Sabo JP, Cooper C et al. The pharmacokinetic interaction between Tipranavir/Ritonavir (500/200) bid and atorvastatin, antacid, and CYP3A4 in healthy adult volunteers. 5nd International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, 1-3 April 2004 [Abstract 5.2].
333. Taylor S, Allen S, Fidler S et al. Stop Study: After discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004 [Abstract 131].
334. Manosuthi W, Sungkanuparph S, Vibhagool A et al. A randomized controlled trial of efavirenz 600 mg/day versus 80 mg/day in HIV-infected patients with tuberculosis to study plasma efavirenx level, virological and immunological outcomes. A preliminary result. XV World AIDS Conference. Bangkok, 2004 [MoOrB1013].
335. Friedland G, jack C, Khoo S, Lalloo U, Naidoo V. Efavirenz levels and clinical outcomes in patients with TB and HIV treated concomitantly with ART and rifampin-containing TB regimen. 12th CROI. Boston, MA, 2005 [Abstract 891].
336. Regazzi M, Maserati R, Villani P et al. Clinical pharmacokinetics of nelfinavir and its metabolite m8 in human immunodeficiency virus (HIV)-positive and HIV-Hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 2005; 49: 643-649.
337. Veronese L, Rautaureau J, Sadler BM et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44: 821-826.
338. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40: 174-181.
339. Bossi P, Peytavin G, Lamotte C et al. High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors. AIDS 2003; 17: 1108-1110.
340. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43: 1071-1087.
341. Alexander CS, Asselin JJ, Ting LS et al. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 2003; 188: 541-548.
342. Liechty C, Alexander C, Harrigan R et al. Are random antiretroviral drug levels associated with objectively measured adherence behaviour? 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 529].
343. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
344. Morris AA, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? Lancet 1999; 354: 1046-1047.
345. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
346. Gervasoni C, Ridolfo AL, Trifiro G et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13: 465-471.
347. Lichtenstein KA, Delaney KM, Ward DJ et al. Changes in HIV-associated fat maldistribution over time. Antivir Ther 2000; 5 (Suppl. 5): 9.
348. Brinkman Y, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 25: 1112-1115.
349. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy [Letter]. AIDS 1999; 13: 2311-2312.
350. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-1883.
351. Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000; 23: 57-76.
352. Moyle G. Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS 2001; 15: 413-415.
353. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors [Letter]. AIDS 1999; 13: 735-737.
354. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-1667.
355. Tashima K, Stryker R, Skeist D et al. Lack of clinical lipodystrophy in patients receiving efavirenz + NRTI in study 006. XXXIX Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 26-29 September 1999 [Abstract 1304].
356. van der Valk M, Gisolf E, Reiss P et al. Increased risk of lipodystrophy when including NRTIs in the treatment of HIV-1 infection with PIs: results from a randomised controlled trial. 2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto, Canada, September 2000 [Abstract P78].
357. Cohen C, Cameron W, Xu Y et al. Effects of NRTI intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in an HIV-infected cohort. 2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto, 13-15 September 2000 [Abstract P56].
358. Mallon PW, Carr A, Cooper DA. HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways. Curr Diab Rep 2002; 2: 116-124, Review.
359. Dube M, Zackin R, Tebas P et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz, or both: A5005s, a study of ACTG 384. Antivir Ther 2002: L18.
360. Cherry CL, Lal L, Thompson KA et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005; 38: 263-267.
361. McComsey GA, Paulsen DM, Lonergan JT et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19: 15-23.
362. McComsey GA, Ward DJ. Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270, Epub 18 December 2003.
363. Bogner JR, Vielhauer V, Beckmann RA et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001; 27: 237-244.
364. Smith DE, Carr A, Law M et al. Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study. AIDS 2002; 16: 2489-2491.
365. Martin A, Smith DE, Mitochondrial Toxicity Study Group et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-1036.
366. Maisonneuve C, Igoudjil A, Begriche K et al. Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir Ther 2004; 9: 801-810.
367. Friis-Moller N, Weber R, DAD study group et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
368. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study. Circulation 1999; 100: 700-705.
369. Wood R, Phanuphak P, Cahn P et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 1: 684-692.
370. Woerle HJ, Mariuz PR, Meyer C et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52: 918-925.
371. Galli M, Veglia F, Angarano G et al. Gender differences in antiretroviral drug-related adipose tissue alterations: women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003; 34: 58-61.
372. Tong Q, Sankale JL, Hadigan CM et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003; 88: 1559-1564.
373. Bastard JP, Caron M, Vidal H et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-1031.
374. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-20254.
375. Rudich A, Vanounou S, Riesenberg K et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001; 50: 1425-1431.
376. Ben-Romano R, Rudich A, Torok D et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003; 17: 23-32.
377. Noor MA, Seneviratne T, Aweeka FT et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16: F1-F8.
378. Lee GA, Seneviratne T, Noor MA et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18: 641-649.
379. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol. Cell Biol 2002; 3: 267-277.
380. Noor MA, Grasela D, Parker RA et al. The effect of atazanavir vs lopinavir/ritonavir on insulin-stimulated glucose disposal rate in healthy subjects. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11 2004 [Abstract 702].
381. Kurowski M, Sternfeld T, Sawyer A, Hill A, Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 2003; 4: 94-100.
382. Moyle G, Baldwin C, Phillpot M. Managing metabolic disturbances and lipodystrophy: diet, exercise, and smoking advice. AIDS Reader 2001; 11: 589-592.
383. Moyle G, Baldwin C. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. AIDS Reader 2000; 10: 479-485.
384. Van Leth F, Hall D, Lange JMA, Reiss P. Increase in high-density lipoprotein cholesterol when using nevirapine and/or efavirenz is maintained up to 2 years. 15th International AIDS Conference. Bangkok, 2004 [Abstract WePpB2065].
385. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284: 472-477.
386. Arioglu E, Duncan-Morin J, Sebring N et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263-274.
387. Calmy A, Hirschel B, Karsegaard L et al. A pilot sstudy for the use of pioglitazone in the treatment of highly active antiretroviral therapy lipodystrophy syndromes. III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Greece, 23-26 October 2001 [Abstract 43].
388. Visnegarwala F, Maldonado MR. Use of PPAR-modulator rosiglitazone in normoglycemic patients with HIV lipodystrophy syndrome. III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Greece, 23-26 October 2001 [Abstract 124].
389. Schwarz et al. The third international workshop on adverse reactions and lipodystrophy in HIV. Athens, Greece, October 2001 [Abstract 27].
390. Moyle GJ, Lloyd M, Reynolds B et al. An open-label, randomised trial of dietary advice with or without pravastatin for the management of protease inhibitor induced hypercholesterolaemia. AIDS 2001; 15: 1503-1508.
391. Miller J, Carr A, Brown D, Cooper DA. A randomised double blind study of gemfibrozil (GF) for the treatment of protease inhibitor-associated hypertriglyceridaemia. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 540].
392. http://www.nhlbi.nih.gov/guidelines/cholesterol (accessed on 26 April 2005).
393. Valantina M, Aubron-Oliviera C, Ghosna J et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17: 2471-2477.
394. Moyle GJ, Lysakova L, Brown S et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Medicine 2004; 5: 82-87.
395. Boix V. Polylactic acid implants. A new smile for lipoatrophic faces? AIDS 2003; 17: 2533-2535.
396. Mest DR, Humble G. Safety and efficacy of intradermal poly-L-lactic acid (Sculptra) injections in patients with HIV-associated facial lipoatrophy. 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington, DC, 2004 [Abstract 59].
397. Hillebrand ME, Strackee SD, van Ulden BGJ. Treatment of facial lipoatrophy with polylactic acid: the PLA-Study. The XIV International AIDS Conference. 2002 [Abstract C 10946].
398. Lafaurie M, Dolivo J, Boulu D et al. Treatment of HIV-associated lipoatrophy of the face with intradermal injections of polylactic acid. 9th Conference on Retroviruses and Opportunistic Infections. J Acquir Immune Defic Syndr 2005; 38: 393-398.
399. Lafaurie, Dolivo M, Boulu D et al. Treatment of facial lipoatrophy with injections of polylactic acid in HIV-infected patients: results from a cohort of 94 patients. 11th CROI. 2004 [Abstract 726].
400. FDA report on polylactic acid. http://aidsinfo.nih.gov/drugs/htmldrug-tech.asp?int_id=0403 2004 (accessed on 26 April 2005).
401. Guaraldi G, Orlando G, De Fazio D et al. Prospective, partially randomized, 24-week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV-related facial lipoatrophy. 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington, DC, 2004 [Abstract 12].
402. Guaraldi G, Orlando G, De Fazio D et al. Autologous fat transfer for the treatment of HIV-related face lipoatrophy: a long follow-up experience. 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington, DC, 2004 [Abstract 87].
403. Levan P, Nguyen TH, Lallemand F et al. Correction of facial lipoatrophy in HIV infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS 2002; 16: 1985-1987.
404. Protopapa C, Sito G, Caporale Dw et al. Bio-Alcamid in druginduced lipodystrophy. J Cosmet Laser Ther 2003; 5: 226-230.
405. Casavantes JC, Gottlieb M. Bio-Alcamid, a high-volume injectable prosthesis for facial reconstitution in HIV-related lipoatrophy: report on 100 patients. 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington, DC, 2004 [Abstract 60].
406. Serra MS, Oyafuso LK. Soft tissue augmentation with polymethymethacylate (PMMA) for correction of lipodystrophy related body fat atrophy. 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington, DC, 2004 [Abstract 49].
407. Oyafuso LKM, Serra MS, Troppe BM. Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5 years follow-up. The XV International AIDS Conference. 2004 [Abstract MoOrB1060].
408. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
409. Carr A, Morey A, Mallon P et al. Fatal portal hypertension, liver failure and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357: 1412-1414.
410. Roy PM, Gouello JP, Pennison-Besnier I et al. Severe lactic acidosis induced by nucleoside analogues in an HIV-infected man. Ann Emerg Med 1999; 34: 282-284.
411. Brivet FG, Nion I, Mégarbane B et al. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction? J Hepatol 2000; 32: 364-365.
412. Brinkman K, Kakuda T. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opinion Infect Dis 2000; 13: 5-11.
413. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22: 911-936.
414. Walker UP, Bickel M, Lutke Volksbeck SI et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in apidose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29: 117-121.
415. Lonergan T, McComsey G, Fisher R et al. Improvements in symptomatic hyperlactatemia are observed after 12 weeks when stavudine is replaced by either abacavir or zidovudine. III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Greece, 2001 [Abstract 81].
416. Mallon P, Sedwell R, Rogers G et al. The efect of rosiglitaozne on PPARaexpression in human adipose tissue is limited by continued exposure to thymidine NRTI. 12th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2005 [Abstract 41].
417. Chatta GT, Arieff AI, Cummings C et al. Lactic acidosis complicating the acquired immunodeficiency syndrom. Ann Intern Med 1993; 118: 37-39.
418. Fortang IS, Belitsos PC, Chaisson RE et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy. Am J Gastroenterol 1995; 90: 1433-1436.
419. John M, Moore CB, James IR et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-723.
420. Lonergan JT, Behling C, Pfander H et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31: 162-166.
421. Gérard Y, Maulin L, Yazdanpanah Y et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723-2730.
422. Acosta BS, Grimsley EW. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South Med J 1999; 92: 421-423.
423. Miller KD, Cameron M, Wood IV et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133: 192-196.
424. Vrouenraets S, Treskes M, Regez RM et al. The occurrence of hyperlactatemia in HIV-infected patients on NRTI treatment. XIII International AIDS Conference. Durban, 2000 [Abstract TuPpB1234].
425. Moyle GJ, Datta D, Mandalia S et al. Hyperlactataemia and Lactic Acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Greece, 2001 [Abstract 98].
426. ter Hofstede HJM, de Marie S, Foudraine NA et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11: 61-66.
427. Chodock R, Myolonakis E, Shemin D et al. Survival of a human immunodeficiency virus patient with nucleoside-induced lactic acidosis: role of haemodialysis treatment. Nephrol Dial Transplant 1999; 14: 2484-2486.
428. Shramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-I minced severe lactic acidosis. Eur J Anaesthesiol 1999; 16: 733-735.
429. Luzzati R, Del Bravo P, DiPerri G et al. Riboflavin and severe lactic acidosis. Lancet 1999; 353: 901-902.
430. Brook MG, Gilson R, Wilkins E, the BHIVA Hepatitis Guidelines Writing Committee. BHIVA Guidelines: HIV and Chronic Hepatitis. Co-Infection with HIV and Hepatitis B Virus Infection. www.bhiva.org.
431. Nelson M, Matthews G, Brook MG, the BHIVA Hepatitis Guidelines Writing Committee. BHIVA Guidelines: HIV and Chronic Hepatitis. Co-Infection with HIV and Hepatitis C Virus Infection. www.bhiva.org.
432. Rockstroh J, Konopnicki D, Soriano V et al. Hepatitis B and Hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2004 [Abstract 799].
433. Lok A. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-1683.
434. Rosenthal E, Poirée M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-1809.
435. Thio C, Seaberg EC, Skolasky R et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
436. Benhamou Y, Bochet M, Thibault V. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999; 30: 1302-1306.
437. Gish R, Leung N, Wang C et al. Resistance to emtricitabine may develops less frequently than to lamivudine. 53rd AASLD. Boston, 2002 [Abstract 838].
438. Nelson M, Porstmouth S, Stebbing J. An open-label study of tenofovir in HIV-1 and hepatitis B virus coinfected individuals. AIDS 2003; 17: F7-F10.
439. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild type hepatitis B virus. Clin Infect Dis 2004; 39: 1062-1064.
440. Dore GJ, Cooper DA, Pozniak A et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-1192.
441. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
442. Carrat F, Bani-Sadr, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848.
443. Chung R, Anderson J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
444. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-281.
445. Kakuda T, Brinkman K. Mitochondrial toxic effects of ribavirin. Lancet 2001; 357: 1802-1803.
446. Montes RML, Rodriguez ZM. Report of three cases of hyperlactacidemia/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients. Rev Clin Esp 2002; 202: 543-545.
447. Sulkowski MS, Thomas D, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with Human Immunodeficiency Virus and the role of Hepatitis B or C infection. JAMA 2000; 283: 74-80.
448. Macias J, Castellano V, Merchante N et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18: 767-774.